title: Human peripheral blood lymphocyte severe combined immunodeficiency (hu-PBL SCID) models of toxoplasmosis.
abstract: Toxoplasmosis is a potentially fatal opportunistic infection of immunocompromised hosts. Improved animal models of toxoplasmosis are needed to more nearly approximate conditions that occur in immunocompromised humans. The development of models of toxoplasmosis using human peripheral blood lymphocytes (hu-PBL) transplanted into severe combined immunodeficiency (SCID) mice is described here. Transplantation of hu-PBL into SCID mice without prior conditioning of the mice resulted in detectable differences in quantitative histological scores of brain inflammation due to Toxoplasma gondii infection, but did not alter mortality when compared to SCID mouse controls. The lack of detectable differences in survival were due to inadequate engraftment of hu-PBL, as assessed by flow cytometry. Unconditioned hu-PBL SCID mice had low titre T. gondii-specific antibody detectable after infection. When pretransplantation conditioning with irradiation and antiasialo GM 1 (n-glucolyl neuraminic acid) antibody was used, prolonged hu-PBL engraftment was observed in SCID mice, which was associated with worsened histopathology and usually impaired survival when compared with SCID mouse controls. When pretransplantation conditioning with irradiation, antiasialo GM antibody and polyethylene glycol-conjugated IL-2 was used, prolonged hu-PBL engraftment was also documented, but this did not affect survival from T. gondii infection when compared with similarly conditioned SCID mouse controls. The latter conditioning protocol resulted in hu-PBL SCID mice producing high titre T. gondii-specific antibody after infection. Conditioned hu-PBL SCID mice had evidence of increased T. gondii-induced inflammatory scores when compared with conditioned SCID mice. These models show promise for the study of the pathogenesis of toxoplasmosis and conditioned hu-PBL SCID mice may have applications for the evaluation of novel therapies for toxoplasmosis in immunocompromised humans.
authors: University of Western Australia, Nedlands, Australia. mbeaman@cyllene.uwa.edu.au
authors: M H
authors: MH
authors: Beaman
authors: J S
authors: JS
authors: Remington
authors: D J
authors: DJ
authors: Meyer
mesh_terms: D000208:Acute Disease; D000818:Animals; D000906:Antibodies / Q000276:immunology; D000913:Antibodies, Protozoan / Q000276:immunology; D002908:Chronic Disease; D003601:Cytotoxicity Tests, Immunologic; D004195:Disease Models, Animal; D005434:Flow Cytometry; D005677:G(M1) Ganglioside / Q000276:immunology; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D008099:Liver / Q000166:cytology / Q000276:immunology; D018655:Lymphocyte Count; D017710:Lymphocyte Transfusion; D051379:Mice; D016513:Mice, SCID; D013154:Spleen / Q000166:cytology / Q000276:immunology; D015996:Survival Rate; D014122:Toxoplasma / Q000276:immunology; D014124:Toxoplasmosis, Animal / Q000276:immunology* / Q000473:pathology; D019172:Transplantation Conditioning; D014916:Whole-Body Irradiation
chemical_list: D000906:Antibodies; D000913:Antibodies, Protozoan; D005677:G(M1) Ganglioside; C018835:asialo GM1 ganglioside